Grünenthal selected BioClinica OnPoint after a thorough evaluation of
the leading enterprise-scale CTMS solutions. The assessment team was
comprised of Grünenthal experts from various functional areas. The
workshops demonstrated that the requirements specified by Grünenthal
could be delivered faster and most cost-effectively using OnPoint.
Grünenthal was particularly impressed with BioClinica’s ability to
integrate with other clinical systems, the extensibility of this
consolidated data via SharePoint-based dashboards and the fact that
OnPoint allows clinical staff to do much of their work within the
familiar environment of Microsoft Office applications.

“After careful review of the commercially available CTMS solutions, we
felt that BioClinica’s platform provides our clinical staff with a
timely and comprehensive overview of relevant data and thus helps to
make planning more efficient,” said Hazel Collie, Head of Quality &
Systems at Grünenthal. “In this regard, OnPoint supports our objective
to enhance our innovation process, allowing us to develop solutions to
improve the quality of life of our patients.”

Mark Weinstein, CEO of BioClinica, said, "We are proud to be selected to
support Grünenthal’s clinical trial support needs, world-wide. This
agreement demonstrates the results of our continuing commitment to
deliver innovative technology solutions that help customers execute and
manage their clinical trials with greater efficiency and speed.”

The Grünenthal Group is an independent, family-owned international
research based pharmaceutical company headquartered in Aachen, Germany.
Building on its unique position in pain, its objective is to become the
most patient-centric company and to be a leader in therapy innovation.
Altogether, the Grünenthal Group has affiliates in 30 countries
worldwide. Grünenthal products are sold in more than 150 countries and
approx. 4,500 employees are working for the Grünenthal Group globally.
In 2010, Grünenthal reached revenues of about 910M €. For more
information: www.grunenthal.com.

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated,
technology-enhanced clinical trial management solutions. BioClinica
supports pharmaceutical and medical device innovation with imaging core
lab, internet image transport, electronic data capture, interactive
voice and web response, clinical trial management and clinical supply
chain design and optimization solutions. BioClinica solutions maximize
efficiency and manageability throughout all phases of the clinical trial
process. With over 20 years of experience and more than 2,000 successful
trials to date, BioClinica has supported the clinical development of
many new medicines from early phase trials through final approval.
BioClinica operates state-of-the-art, regulatory-body-compliant imaging
core labs on two continents, and supports worldwide eClinical and data
management services from offices in the United States, Europe and Asia.
For more information, please visit www.bioclinica.com

Certain matters discussed in this press release are “forward-looking
statements” intended to qualify for the safe harbors from liability
established by the Private Securities Litigation Reform Act of 1995.In
particular, the Company’s statements regarding trends in the marketplace
and potential future results are examples of such forward-looking
statements. The forward-looking statements include risks and
uncertainties, including, but not limited to, the consummation and the
successful integration of current and proposed acquisitions, the timing
of projects due to the variability in size, scope and duration of
projects, estimates and guidance made by management with respect to the
Company’s financial results, backlog, critical accounting policies,
regulatory delays, clinical study results which lead to reductions or
cancellations of projects, and other factors, including general economic
conditions and regulatory developments, not within the Company’s control.The factors discussed herein and expressed from time to time in the
Company’s filings with the Securities and Exchange Commission could
cause actual results and developments to be materially different from
those expressed in or implied by such statements.The
forward-looking statements are made only as of the date of this press
release and the Company undertakes no obligation to publicly update such
forward-looking statements to reflect subsequent events or circumstance.
You should review the Company’s filings, especially risk factors
contained in the Form 10-K and the recent Form 10-Q.